HLA-DRB5 and neoplasm: A similar situation was observed in the case of a KRASG12V-specific, HLA-DRB5*01:01–restricted TCR, which could recognize HLA-matched B cells, but not MHC-II–expressing tumor cells, when antigen was directed to the MHC-II presentation pathway.